These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 7680860)
1. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860 [TBL] [Abstract][Full Text] [Related]
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676 [TBL] [Abstract][Full Text] [Related]
3. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Jackman AL; Gibson W; Brown M; Kimbell R; Boyle FT Adv Exp Med Biol; 1993; 339():265-76. PubMed ID: 7513935 [TBL] [Abstract][Full Text] [Related]
4. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Ward WH; Kimbell R; Jackman AL Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289 [TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277 [TBL] [Abstract][Full Text] [Related]
7. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Sikora E; Jackman AL; Newell DR; Calvert AH Biochem Pharmacol; 1988 Nov; 37(21):4047-54. PubMed ID: 2461200 [TBL] [Abstract][Full Text] [Related]
8. Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor. Yin MB; Guimaraes MA; Zhang ZG; Arredondo MA; Rustum YM Cancer Res; 1992 Nov; 52(21):5900-5. PubMed ID: 1394217 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518 [TBL] [Abstract][Full Text] [Related]
10. Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Pressacco J; Erlichman C Biochem Pharmacol; 1993 Dec; 46(11):1989-97. PubMed ID: 8267649 [TBL] [Abstract][Full Text] [Related]
11. Syntheses and thymidylate synthase inhibitory activity of the poly-gamma-glutamyl conjugates of N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino ]-2-thenoyl]-L-glutamic acid (ICI D1694) and other quinazoline antifolates. Bisset GM; Pawelczak K; Jackman AL; Calvert AH; Hughes LR J Med Chem; 1992 Mar; 35(5):859-66. PubMed ID: 1372358 [TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates. Jackman AL; Marsham PR; Moran RG; Kimbell R; O'Connor BM; Hughes LR; Calvert AH Adv Enzyme Regul; 1991; 31():13-27. PubMed ID: 1877386 [TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase. Rathod PK; Reshmi S Antimicrob Agents Chemother; 1994 Mar; 38(3):476-80. PubMed ID: 8203840 [TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. Li WW; Tong WP; Bertino JR Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025 [TBL] [Abstract][Full Text] [Related]
15. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays. Schöber C; Gibbs JF; Yin MB; Slocum HK; Rustum YM Biochem Pharmacol; 1994 Aug; 48(5):997-1002. PubMed ID: 8093112 [TBL] [Abstract][Full Text] [Related]
16. ICI D1694, an inhibitor of thymidylate synthase for clinical study. Jackman AL; Jodrell DI; Gibson W; Stephens TC Adv Exp Med Biol; 1991; 309A():19-23. PubMed ID: 1789205 [TBL] [Abstract][Full Text] [Related]
17. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Hanlon MH; Ferone R Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats. Jodrell DI; Newell DR; Gibson W; Hughes LR; Calvert AH Cancer Chemother Pharmacol; 1991; 28(5):331-8. PubMed ID: 1914075 [TBL] [Abstract][Full Text] [Related]
19. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. Keyomarsi K; Samet J; Molnar G; Pardee AB J Biol Chem; 1993 Jul; 268(20):15142-9. PubMed ID: 8325888 [TBL] [Abstract][Full Text] [Related]
20. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Pressacco J; Mitrovski B; Erlichman C; Hedley DW Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]